My watch list  

An av‐RGD integrin inhibitor toolbox: drug discovery insight, challenges and opportunities

There is a requirement for efficacious and safe medicines to treat diseases with high unmet need. The resurgence in av RGD integrin inhibitor drug discovery is poised to contribute to this requirement. However, drug discovery in the av integrin space is notoriously difficult due to the receptors being structurally very similar as well as the polar zwitterionic nature of the pharmacophore. This review aims to guide drug discovery research in this field through an av inhibitor toolbox, consisting of small molecules and antibodies. Small molecule av tool compounds with extended profiles in avb1, 3, 5, 6 and 8 cell adhesion assays, with key physicochemical properties, have been collated to assist in the selection of the right tool for the right experiment. This should also facilitate an understanding of partial selectivity profiles of compounds generated in different assays across research institutions. Prospects for further av integrin research and the critical importance of target validation are discussed, where increased knowledge of the selectivity for individual RGD v integrins is key. Insights into the design of small molecule RGD chemotypes for topical or oral administration are provided and clinical findings on advanced molecules are examined.

Authors:   Richard Hatley, Simon Macdonald, Robert Slack, Joelle Le, Steve Ludbrook, Pauline Lukey
Journal:   Angewandte Chemie International Edition
Year:   2017
Pages:   n/a
DOI:   10.1002/anie.201707948
Publication date:   25-Sep-2017
Facts, background information, dossiers
  • drug discovery
  • selectivity
  • Research
  • receptors
  • molecules
  • integrins
  • diseases
  • cell adhesion
More about Wiley
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE